HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Lowers Price Target to $66
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on SpringWorks Therapeutics (NASDAQ:SWTX) but lowers the price target from $105 to $66.

August 07, 2023 | 10:21 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
SpringWorks Therapeutics' price target has been lowered from $105 to $66 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100